OUR NEW PROFILE IS:  (NASDAQ: MODD)

MODULAR MEDICAL ANNOUNCES COLLABORATION WITH GLOOKO

THERE ARE 1.9 MILLION INDIVIDUALS WITH TYPE 1 DIABETES IN THE US.  100% OF PATIENT POPULATION REQUIRE DAILY INSULIN INJECTION. ONLY 1 OUT OF 3 CURRENTLY USE AN INSULIN PUMP

WE HAVE SEEN INSIDERT PURCHASE OVER 575K SHARES IN THE PAST 12 MONTHS WITH ZERO SALES

ACCORDING TO THE DECEMBER INVESTOR PRESENTATION, THE COMPANY IS EXPECTING TO SUBMIT ITS MODD1 DEVICE FOR FDA CLEARANCE THIS MONTH

Hello Everyone,  

We have a new profile that we want you to research for Tuesday’s session.

This is another company that we have never have featured on our newsletter before with an incredible looking chart.

Pull up MODD Immediately.  

Modular Medical, Inc. (Nasdaq:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.”

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump.

The American Diabetes Association says that “In 2021, 38.4 million Americans, or 11.6% of the population, had diabetes.” It released a report in 2022 that estimated the annual cost of diabetes to be $412.9 billion. 

“People with diagnosed diabetes now account for one of every four health care dollars spent in the U.S.” the report noted.

Citing 2020 data from the Centers for Disease Control and Prevention, MODD points out that 3.6 million Americans require daily insulin — that includes 2.9 million who use multiple daily injections (MDI) and 670,000 who use insulin pumps:

(CGM stands for ‘continuous glucose monitors’)

Of those who use MDI, research firm Seagrove Partners has found that about 25% are “almost pumpers” — “meaning that they have considered going on a pump, understand pump therapy benefits, but want something simpler that doesn’t have all the ‘bells and whistles’.”

That’s where MODD expects to come in. The company believes that existing insulin pumps are geared toward “superusers” and are “prohibitive for many to learn and manage.” 

The pumps have too many complicated features that most diabetics don’t need. This increases costs and puts them out of reach for many. As the tagline on MODD’s website reads, it aims to provide “diabetes care for the rest of us.”

INSIDERS ARE CLEARLY “PUMPED” REGARDING THE FUTURE OF THE COMPANY.  WE HAVE SEEN OVER 575K SHARES PURCHASED IN THE PAST 12 MONTHS WITH ZERO SALES. MODD IS SITTING WELL ABOVE THE 52 WEEK LOW OF .84 AND WAS SITTING AT A BUCK LESS THAN 2 MONTHS AGO.  IT RECENTLY RAN WELL OVER 100% TO HIGHS OF 2.22 AND AT THE 1.70 LEVEL IT IS STILL SITTING UP OVER 70% FROM THE END OF NOVEMBER EVEN AFTER SOME PROFIT TAKING.  

MODD1 — THE ADVANCED INSULIN PUMP DESIGNED TO OPEN ACCESS

New microfluidics technology allows for low-cost pumping of insulin.

New intuitive design makes the product simple to use and easier to prescribe

90 Day Reusable

3 Day Consumable

*****Products are currently under research and development and are not available for investigational use or sale.

MODD1 SYSTEM WILL TRANSFORM THE USER/PROVIDER EXPERIENCE

EASY START

Free samples at point-ofcare, payer support, refill RX at pharmacy.

One hour training with care provider (telehealth or clinician in office)

Red, yellow and green light system on the pump indicate how it’s working.

When ready for mealtime bolus, press the button on the pump and confirm

Easy to remove simply click it off and put it back on freely (adhesive or strap).

After 90 days, seamlessly transfer settings to the next 90-day pump

EASY TO CONNECT

All data is securely stored on the cloud, easily accessed by clinicians, data access will enable coverage for diabetes management time

MODULAR MEDICAL STANDS OUT FROM THE REST

T1D Insulin Pump Comparisons (US Market)

PRODUCT FEATURES	MODD1	T:SLIM X2	MEDTRONIC 760G	OMIPOD DASH
Manufacturer	Modular Medical	Tandem Diabetes Care	Medtronic (MiniMed)	Insulet
Reservoir Size	300 units/3mL	300 units/3mL	300 units/3mL	200 units/2mL
Pump Cost	Pump:$0 3-Day Disposables: $349/mo (PBM Pricing)	Pump:$4,200 Disposables: $134/mo	Pump:$4,600 Disposables: $148/mo	Pump:$0 Disposables: $347/mo (PBM Pricing)
Monitorable Via Cell Phone	Yes	No	Yes	No
External Controller Required	No	No	No	Yes
Charger/Battery	No Charger/Single-use disposable battery provided	Charger Required	Battery Required	Handset Charging Required
Easy to Learn	Yes	No	No	No
Remove & Reattach	Yes	Yes	Yes	No

MODULAR MEDICAL ANNOUNCES COLLABORATION WITH GLOOKO

SAN DIEGO, CA / ACCESSWIRE / December 21, 2023 / Modular Medical, Inc. (Nasdaq:MODD) (“Modular Medical” or the “Company”), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced a collaboration agreement with Glooko, Inc., a global leader specializing in connected care and remote patient monitoring for diabetes. Integrating with Glooko will allow clinicians and patients to easily review insulin dosing data from the MODD1 pump, when commercially available. In addition, through Glooko’s platform, Dexcom CGMS users will be able to view their glucose levels in the same accessible format in conjunction with their pump data.

Glooko’s platform has a broad installed base, which has been deployed in over 30 countries and 8,000 clinical locations.

“We are extremely pleased to add the Glooko technology platform to our diabetes care system making it even easier and more cost effective for us to provide this important capability to our clinical and patient base. Glooko’s mission to improve health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform fits perfectly with our vision of providing an easy to use, affordable delivery technology to give more patients access to better care,” said Jeb Besser, CEO of Modular Medical.

About Glooko

Glooko improves health outcomes of people with diabetes and related chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations. For more information, please visit glooko.com.

NEWS

DEC 21, 2023 08:00AM

MODULAR MEDICAL ANNOUNCES COLLABORATION WITH GLOOKO

DEC 11, 2023 11:30AM

REGISTRATION IS NOW OPEN FOR TRIBE PUBLIC’S WEBINAR EVENT “DIABETES CARE FOR THE REST OF US.” FEATURING MODULAR MEDICAL CEO ON FRIDAY, DECEMBER 15, 2023

OCT 31, 2023 11:00AM

MODULAR MEDICAL UPDATES TEST PROGRESS AND SUBMISSION TIMELINE

AUG 16, 2023 04:01PM

MODULAR MEDICAL PARTNERS WITH PHILLIPS-MEDISIZE TO EXPAND INSULIN DELIVERY ALTERNATIVES

JUL 06, 2023 08:30AM

MODULAR MEDICAL ANNOUNCES DIABETES INDUSTRY VETERAN DUANE DESISTO WILL JOIN THE BOARD OF DIRECTORS

MAY 25, 2023 04:05PM

MODULAR MEDICAL ANNOUNCES FULL EXERCISE OF UNDERWRITER’S OPTION TO PURCHASE ADDITIONAL SHARES

MAY 16, 2023 08:35AM

MODULAR MEDICAL ANNOUNCES PRICING OF UPSIZED $9.4 MILLION PUBLIC OFFERING

JAN 25, 2023 09:00AM

MODULAR MEDICAL PROVIDES UPDATE ON FDA SUBMISSION STRATEGY

NOV 28, 2022 12:30PM

MODULAR MEDICAL ANNOUNCES PRODUCT TESTING UPDATE

NOV 23, 2022 09:00AM

MODULAR MEDICAL ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR CONFERENCES

OCT 03, 2022 09:00AM

MODULAR MEDICAL PROVIDES PRODUCT UPDATE

SEP 07, 2022 11:00AM

MODULAR MEDICAL ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR CONFERENCES

AUG 11, 2022 09:00AM

DR. ANNE PETERS JOINS THE MODULAR MEDICAL ADVISORY BOARD

JUL 26, 2022 09:00AM

MODULAR MEDICAL APPOINTS KEVIN SCHMID AS CHIEF OPERATING OFFICER

JUN 02, 2022 04:00PM

MODULAR MEDICAL TO PRESENT AT LD MICRO INVITATIONAL XII INVESTOR CONFERENCE

MANAGEMENT TEAM

PAUL DIPERNA

FOUNDER AND PRESIDENT

Paul leads the Modular Medical organization. He possesses over 30 years of experience in the medical device industry as a technologist, business executive and founder of several successful startups. He has been deeply involved in Diabetes care for the past 20 years.

Paul’s early background includes key roles at Baxter Healthcare where he worked in cell separation product design, high volume manufacturing, business development, initial startups to evaluate technology within the spaces between divisions, corporate project management and technical diligence on acquisitions. Upon leaving Baxter in 2003, Paul founded, created the technology, and was CEO and board member for a diabetes delivery innovation that bec

JAMES (JEB) BESSER

CHIEF EXECUTIVE OFFICER

23 year Managing Member, Manchester Management LLC, largest shareholder of Modular Medical, Inc.

25+ years of U.S. public equity and capital markets experience, with a focus in life science and technology

Provided long term strategic planning and due diligence, business development, and investor relations guidance to over 100 public companies

Active involvement in developing Modular Medical’s commercial go to market strategy since 2017

JAMES SULLIVAN

INTERIM CHIEF FINANCIAL OFFICER

Jim leads finance and administrative functions and brings over 30 years of financial management and accounting experience to Modular Medical. Based in Silicon Valley, he is a hands-on, seasoned CFO with significant public-company experience in hardware, software and cloud-services businesses and has completed over 15 financings. He has held CFO positions at MoSys, Inc., Apptera, Inc. and 8×8, Inc. Prior to his tenure as CFO at these companies, he held various positions in the assurance practice at PricewaterhouseCoopers LLP in New York and Silicon Valley. He holds a bachelor of science in accounting from New York University, Stern School of Business and is an active certified public accountant.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY MODD AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.